Search Results - "De Forni, M"

CPT-11 (Irinotecan) in the treatment of colorectal cancer by Armand, J.P, Ducreux, M, Mahjoubi, M, Abigerges, D, Bugat, R, Chabot, G, Herait, P, de Forni, M, Rougier, P

“…Colorectal cancer is one of the most common cancers in the Western World. Although 50% of patients are cured by surgery alone, the outcome is poor in high-risk…”
Get full text

CPT-11-induced cholinergic effects in cancer patients by Gandia, D, Abigerges, D, Armand, J P, Chabot, G, Da Costa, L, De Forni, M, Mathieu-Boue, A, Herait, P

Get more information

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study by de Forni, M, Malet-Martino, M C, Jaillais, P, Shubinski, R E, Bachaud, J M, Lemaire, L, Canal, P, Chevreau, C, Carrié, D, Soulié, P

“…A prospective clinical study was performed to determine the incidence of high-dose continuous intravenous infusion fluorouracil (5FU-CIV) cardiotoxicity. Three…”
Get more information

A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma by Rougier, P., Adenis, A., Ducreux, M., de Forni, M., Bonneterre, J., Dembak, M., Clouet, P., Lebecq, A., Baille, P., Lefresne-Soulas, F., Blanc, C., Armand, J.P.

“…The aim of this study was to evaluate the efficacy of docetaxel as first-line chemotherapy in patients with unresectable metastatic or locally advanced…”
Get full text

A phase II study of docetaxel in patients with metastatic squamous cell carcinoma of the head and neck by COUTEAU, C, CHOUAKI, N, ARMAND, J.-P, LEYVRAZ, S, OULID-AISSA, D, LEBECQ, A, DOMENGE, C, GROULT, V, BORDESSOULE, S, JANOT, F, DE FORNI, M

“…This study was designed to evaluate the activity, safety and tolerance of docetaxel (D) in a selected population with metastatic squamous cell carcinoma of the…”
Get full text

Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients by DE FORNI, M, BUGAT, R, CHABOT, G. G, CULINE, S, EXTRA, J.-M, GOUYETTE, A, MADELAINE, I, MARTY, M. E, MATHIEU-BOUE, A

“…Irinotecan (CPT-11) is a novel water-soluble, semisynthetic derivative of camptothecin, with inhibitory effects on mammalian DNA topoisomerase I, high…”
Get full text

Cardiotoxicity of chemotherapy by de Forni, Marcel, Armand, Jean-Pierre

“…With the use of hematologic support (colony stimulating factors and autologous bone marrow transplantation) for the control of chemotherapy-induced…”
Get full text

Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trials by Chabot, G G, Abigerges, D, Catimel, G, Culine, S, de Forni, M, Extra, J M, Mahjoubi, M, Hérait, P, Armand, J P, Bugat, R

“…Irinotecan (CPT-11) is a novel water-soluble camptothecin derivative selected for clinical testing based on its good in vitro and in vivo activity in various…”
Get more information

Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil by Wibault, P, Bensmaine, M A, de Forni, M, Armand, J P, Tellez Bernal, E, Guillot, T, Recondo, G, Domenge, C, Janot, F, Borel, C, Luboinski, B, Eschwege, F, Cvitkovic, E

“…To evaluate an intensive concomitant chemoradiotherapy protocol of conventional radiotherapy with intermittent cisplatin (CDDP) and continuous-infusion…”
Get more information

Phase I and pharmacokinetic study of brequinar (DUP 785; NSC 368390) in cancer patients by de Forni, M, Chabot, G G, Armand, J P, Fontana, X, Recondo, G, Domenge, C, Carde, P, Barbu, M, Gouyette, A

“…Brequinar (DUP 785, NSC 368390) is a 4-quinoline carboxylic acid derivative with broad spectrum antitumour activity in experimental models that acts as an…”
Get more information

Phase II study of pirarubicin (THP) in patients with cervical, endometrial and ovarian cancer: study of the Clinical Screening Group of the European Organization for Research and Treatment of Cancer (EORTC) by Chauvergne, J, Fumoleau, P, Cappelaere, P, Metz, R, Armand, J P, Chevallier, B, Kerbrat, P, de Forni, M, Lhommé, C, Roche, H

“…From 1986 to 1990, a multicentric phase II study was conducted with pirarubicin, a new semi-synthetic anthracyclin[4'-O-tetrahydropyranyl-adriamycin (THP)]. 87…”
Get more information

Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug by LEMAIRE, L, MALET-MARTINO, M. C, DE FORNI, M, MARTINO, R, LASSERRE, B

“…The cardiotoxicity of 5-fluorouracil (FU) was attributed to impurities present in the injected vials. One of these impurities was identified as…”
Get full text

Determination of the urinary excretion of ifosfamide and its phosphorated metabolites by phosphorus-31 nuclear magnetic resonance spectroscopy by GILARD, V, MALET-MARTINO, M. C, DE FORNI, M, NIEMEYER, U, ADER, J. C, MARTINO, R

“…Phosphorus-31 nuclear magnetic resonance spectroscopy was used to analyze urine samples obtained from patients treated with ifosfamide (IF). This technique…”
Get full text

Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study by Chabot, G G, Armand, J P, Terret, C, de Forni, M, Abigerges, D, Winograd, B, Igwemezie, L, Schacter, L, Kaul, S, Ropers, J, Bonnay, M

“…The purpose of this study was to determine the bioavailability (F) of etoposide (E;VP-16) after oral administration of the water-soluble prodrug etoposide…”
Get more information

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies by Chatelut, E, de Forni, M, Canal, P, Chevreau, C, Roche, H, Plusquellec, Y, Johnson, N P, Houin, G, Bugat, R

“…Cisplatin and teniposide given by intraperitoneal (IP) route exert a synergistic therapeutic effect against ascitic P388 leukemia in mice. As single agents,…”
Get more information

Pharmacokinetics of carboplatin in a patient suffering from advanced ovarian carcinoma with hemodialysis-dependent renal insufficiency by Chatelut, E, Rostaing, L, Gualano, V, Vissac, T, De Forni, M, Ton-That, H, Suc, J M, Houin, G, Canal, P

“…Pharmacokinetics of carboplatin were determined in a patient suffering from advanced ovarian cancer with total hemodialysis-dependent chronic renal failure…”
Get more information

Specificity of the phase I trial for cytotoxic drugs in oncology by Armand, J P, Klink-Alakl, M, Recondo, G, de Forni, M

“…The phase I trial in oncology follows a very different methodology than in other areas of medicine. Its main objective is the identification of the maximal…”
Get more information

Flavonoids: a new class of anticancer agents? Preclinical and clinical data of flavone acetic acid by Armand, J, De Forni, M, Recondo, G, Cals, L, Cvitkovic, E, Munck, J

Get more information

Chronopharmacokinetics of doxorubicin in patients with breast cancer by CANAL, P, SQALLI, A, DE FORNI, M, CHEVREAU, C, PUJOL, A, BUGAT, R, ROCHE, H, OUSTRIN, J, HOUIN, G

“…The chronopharmacokinetics of doxorubicin (DOX) has been studied in 18 patients suffering from breast cancer. They received combined chemotherapy including DOX…”
Get full text

Flucytosine conversion to fluorouracil in humans : does a correlation with gut flora status exist .? A report of two cases using fluorine-19 magnetic resonance spectroscopy by MALET-MARTINO, M. C, MARTINO, R, DE FORNI, M, ANDREMONT, A, HARTMANN, O, ARMAND, J. P

“…A relationship between the gut flora level, particularly gram-negative enterobacilli, and the in vivo flucytosine conversion to fluorouracil has been observed…”
Get full text